Programme

Education: in 1986, graduated with distinction from the Therapeutic Department of Moscow Institute of Medicine and Dentistry. Subsequently did post graduate studies, specialising in Urology in Moscow, Germany, France and the USA. He is the sole Russian urologist certified by the Higher European Urological Commission. He has performed the largest number of urological reconstructive plastic surgery operations in women. He has the most experience of performing surgical treatment of prostate cancer in the Russian Federation, including over one thousand robot-assisted radical prostatectomies. 2011: President of the European Academy of Urology. Since 2010, in conjunction with leading engineers, had been developing a Russia robot-surgery complex. Prof. Pushkar regularly performs demonstration operations and gives topical courses in Europe and the USA. He is the author of over 1000 scientific articles and 50 monographs in Russia and abroad.

Ramil Khabriev is an academician at the Russian Academy of Sciences. Ramil Khabriev is an Honoured medical Doctor of the Russian Federation. He received the Russian government Science and Technology Prize in 2008 and was honoured with an Order of Merit to the Fatherland, IV class, as well as other Russian government awards. He graduated from the S.V. Kurashov Kazan Medical Institute. He served as Minister of Healthcare of the Republic of Tatarstan from 1989 to 1994 and as a people’s deputy and member of the Council of Nationalities for the Supreme Council of the Russian Federation, from 1990 to 1993. From 1994 to 2001, he was head of the Department of State Control of Quality, Effectiveness, and Medication Safety at the Russian Ministry of Healthcare. He served as General Director of Biopreparat, in Moscow, from 2001 to 2004. From 2004 to 2009, Ramil Khabriev was head of the Federal Service for the Monitoring of Healthcare (Roszdravnadzor). He was the deputy director of the Department of Social Development of the Government of the Russian Federation, from 2007 to 2009. From 2009 to 2012, he was the First Vice Rector of the N.I. Pirogov Russian National Research Medical University.

Dan Brindle currently serves as GlaxoSmithKline’s Vice President of Government Affairs (Emerging Markets, Australasia, China and Japan) and is head of the company’s Global Patient Advocacy team. Since 1999, he has held number of leadership roles with Eli Lilly and Company, Pfizer and GlaxoSmithKline, including commercial operations / country management, and government affairs and public policy. He has spent the majority of his career based in Asia, including assignments in Beijing, Hong Kong and Singapore. He was involved in the creation of the Asia Pacific Economic Cooperation Life Sciences Initiative, and has continued to stay involved with the APEC process as an industry adviser and participant throughout his career in the pharmaceutical industry. In this time, he has had the opportunity to counsel governments across the Emerging Markets around healthcare policy and development issues, and was involved in the formation of the Thai Center for Excellence in the Life Sciences (T-CELS), a government body created to foster innovation and investment in the life sciences sector in Thailand. An American attorney licensed before the State Bar of California, Dan previously served as Legislative Counsel and close personal advisor to former United States Senator Frank H. Murkowski (Alaska) from 1996 – 1999, and was involved in a wide range of international foreign policy and energy issues, as well as domestic policies impacting healthcare, finance and Native American issues. He is fluent in Mandarin Chinese, and currently resides in Singapore.

Elena Bushberg leads Veropharm, which became part of Abbott in 2014, since February 2015. Prior to being named in this role, Elena was Director of Cardiology & Neurology for Abbott’s Established Pharmaceuticals business in Russia. Before joining Abbott, Elena held different positions in finance, marketing and business operations at Schering-Plough and MSD. Elena obtained a degree in philology from Moscow State Linguistic University as well as an Executive MBA degree from the Duke University, USA

CEO, Association of Russian Pharmaceuticals Manufacturers, member of the Board, Russian Union of Industrialists and Entrepreneurs, member of the Council, Chamber of Trade and Industry of the Russian Federation PhD in Medicine, a degree from I.M. Sechenov First Moscow Institute of Medicine. In 2002, he co-founded the Association of Russian Pharmaceuticals Manufacturers and led it until 2004. From 2004 to 2007, he was Deputy Director of Federal State-Owned Institution Research Center for Testing of Medical Applications under the Russian Service for Supervision of Healthcare. In October 2007, a general meeting of the Association once again elected Victor Dmitriev its CEO. Founded in 2002, the Association of Russian Pharmaceuticals Manufacturers includes leading Russian pharmaceutical companies with around 75% of Russia’s medicine output, more than 40% of exports, and more than 80% of domestically produced medicines for the Essential Medicines Provision Program. The Association’s mission is to develop the Russian pharmaceutical industry to ensure the necessary supplies of modern, quality, and affordable medicines to the public.

Elena Kartasheva joined Abbott Russia in July 2014 as General Manager for the company. In her role, Elena is focused on expanding Abbott’s Established Pharmaceuticals business in Russia including further development of the pharmaceutical product portfolio. Prior to joining Abbott, Elena headed Meda Pharmaceuticals in Russia for three years managing a wide portfolio of products across multiple market segments including prescription medicines, hospital and OTC. Previously she worked for Sanofi, Novartis Group and Pliva (TEVA) in a variety of sales, marketing and business unit head roles. Elena holds a PhD in Oncology as well as a Masters in Medicine from the Sechenov Moscow State Medical University, Department of General Medicine.

Eric Cornut has been appointed Special Envoy of the CEO, effective 1 June 2016. From August 2014 to May 2016, Mr. Cornut served as Chief Ethics, Compliance and Policy Officer of Novartis, in addition to his role as Chairman of Novartis Group Japan. Previously, Mr. Cornut assumed the role of Chief Commercial Officer of Novartis Pharmaceuticals and earlier, he led Pharma Europe. Prior to that, he served as the Chief Executive Officer for Novartis Netherlands and Novartis France. Earlier in his career, Mr. Cornut played a key role in the merger of Ciba-Geigy and Sandoz. Mr. Cornut has a Doctoral degree in Law from the University of Basel, Switzerland, and a Master of Law degree from the University of California, Berkeley, in the United States.

Vice-President for Government Relations at Sanofi. Born in 1965. Graduated French Military Academy of Sainte Syre and Higher Military College. After a few officer posts received colonel rank June 1, 2008. Posts included service at a number of French embassies and army headquarters in Spain, Chile, Argentina and El Salvador. Between 2003 and 2005 was a councilor to the Minister of the Internal Affairs of France. Joined Sanofi in April 2009 as Vice-President for GR in the intercontinental region, including Sanofi activity in the developing countries. Recipient of the National Order of the Legion of Honour, Order of the Merit for the Motherland, United Nations Medal.

Date of birth: February 1, 1965 Place of birth: Moscow Marital status: Married, with three children Dmitry Morozov is a member of the Council for Development of the Pharmaceutical and Medical Industry attached to the Government of the Russian Federation. He is on the list of the Top 500 reserve management executives under the auspices of the President of the Russian Federation.Dmitry Morozov graduated from the Radio Technology Department of the State Academy of Consumer Services in Moscow. 1997–1998: Studied at the Plekhanov Russian Academy of Economy in Moscow, Department of Finance and Credit. Earned a diploma in Economics. 1998: Successfully completed an MBA programme at the MIRBIS Moscow International Higher School of Business and obtained an MBA in Management. 2004: Studied at the Keio Business School in Japan under a presidential programme. 1993–2002: Vice Chairman of the Management Board, CentroCredit Bank. 2001: Founded CJSC Biocad; currently serves as its President. Biocad manufactures ready-made medicines, pharmaceutical substances and genetic engineering products.

Since October 2014, Iskra Reic has held the position of General Manager of AstraZeneca Russia. Since June 2016, she has also been Russia & Eurasia Area Vice President. Iskra Reic thus currently heads the AstraZeneca business in Russia, as well as in Russia & Eurasia Area. Iskra Reic joined AstraZeneca Russia in 2012 as Marketing Director. Before coming to Russia, she held managerial roles at AstraZeneca Central & Eastern Europe, Middle East and Africa area, as well as at branches of the company in Eastern Europe. Overall, Iskra Reic has worked at AstraZeneca since 2001. Iskra Reic holds a Master’s degree in dentistry and an MBA from the Business School IEDC Slovenia. Before joining AstraZeneca, she worked as a dentist and participated in implementing the national programme for preventive medicine and public health by the Ministry of Health of Croatia.

Born in Moscow, Russia on 27 August 1979.Graduated from the State University “Higher School of Economics”, Diploma in Economy and Business Administration.Since 1995 in Healthcare and Pharmaceutics.R-Pharm Founder. President of All-Russia Business Association “Delovaya Rossiya” (“Business Russia”), actively participating in the improvement of investment climate in the Russian Federation and the establishment of the regional investment standard.Member of the Economic Council under the President of the Russian Federation.Member of the Presidential Council for Priority National Projects and Demographic Policy.Member of the Expert Council under the Government of the Russian Federation. Member of the Public Chamber of the Russian Federation, Head of Commission on Investment Climate.Representative (public ombudsman) of the Commissioner of the Presidential Council on the protection of the rights of entrepreneurs on issues related to the protection of the rights of foreign investors.Board-member and Co-chairman of Committee of the Russian Union of Industrialists and Entrepreneurs on pharmaceutical and medical industry.Co-Chairman of the National Rating CommitteeMember of the Public Council under the Ministry of Industry and Trade of the Russian Federation (pharmaceutical, medical equipment and technologies).Member of the Supervisory Board of the Autonomous Nonprofit Organization "Agency for Strategic Initiatives".

Date of birth: 29 April 1968 Place of birth: Obninsk, Kaluga Region Education: Graduated from G.V. Plekhanov Russian Academy of the Economics, PhD in Economics Work history: 1991–2007: Executive positions in various businesses 2007–2008: Director, Chemical Technology Complex and Bio-Engineering Technology Department of the Ministry of Industry and Energy of the Russian Federation 2008–2013: Director, Chemical Technology Complex and Bio-Engineering Technology Department of the Ministry of Industry and Trade of the Russian Federation Since 2013: Deputy Minister of Industry and Trade of the Russian Federation Awards: 2009: Mercy honorary badge from the Ministry of Healthcare and Social Development of the Russian Federation 2011: Honorary Chemist title from the Ministry of Industry and Trade of the Russian Federation 2011: Prize of the Government of the Russian Federation in the field of science and technology for development and implementation of the scientific fundamentals of the national system of chemical product turnover safety 2015: Medal of the Service to the Motherland Order 2nd Degree Civil rank: Full State Councillor of the Russian Federation, 1st Class

Education: 1974 – Military Institute of Foreign Languages. 1991 – Russian State University for the Humanities. Professional activities: Mr. Shipkov began his career in law enforcement. From 1998 to 2000, he was a board member of the State Customs Committee of the Russian Fed-eration. In 1999, he was appointed director of the Personnel Department and a board member of the State Customs Committee and then worked in the State Duma administrative office. From 2000 to 2004, he served as director of pharmaceutical inspections at the Ministry of Healthcare. In 2004, he was appointed deputy director of the Federal Service for Intellectual Property, Patents and Trademarks (Rospatent). He also took part in the work of a medicine licensing commission of the Federal Service for the Supervision of Public Health and Social Development. Since 2007, he has been the executive director of AIPM.